Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer
Nivolumab offers a superior survival benefit over docetaxel in patients with advanced, previously treated non-small-cell lung cancer (NSCLC). An association between programmed cell death ligand-1 (PD-L1) expression and the efficacy of nivolumab has been reported in many studies. However, the associa...
-д хадгалсан:
| Үндсэн зохиолчид: | , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Хэл сонгох: | англи |
| Хэвлэсэн: |
2017
|
| Онлайн хандалт: | https://doi.org/10.18632/oncotarget.21602 https://www.oncotarget.com/article/21602/pdf/ |
| Шошгууд: |
Шошго нэмэх
Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!
|